Drug intelligence / Profile preview

dieda wan

Development stage: Unknown
Lead developer: Liaoning Jindan Pharmaceutical
Administration: Oral

Overview

Dieda Wan is a traditional Chinese medicine (TCM) bolus developed and manufactured by Liaoning Jindan Pharmaceutical. It is an approved pharmaceutical product in China, primarily indicated for the treatment of traumatic injuries, including bruises, contusions, and physical trauma resulting in pain and swelling. The formulation is designed to promote blood circulation, disperse blood stasis, and reduce inflammation and pain. As a multi-ingredient TCM, it typically incorporates various herbal components such as Panax notoginseng (Sanqi) and Carthamus tinctorius (Honghua), which are recognized in traditional medicine for their hemostatic and analgesic properties.

Brand names: 跌打丸
Other names: Dieda PillsTraumatic Injury Pills

Beyond the preview

Go deeper on dieda wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dieda wan.

Explore the full profile